Search

We conducted a phase II study to determine the availability and safety of combination chemotherapy with weekly paclitaxel and doxifluridine (a capecitabine metabolite) in the treatment of advanced or recurrent breast cancer. Patients were treated with a combination chemotherapy regimen: doxifluridine was orally administered at 800 mg/day for 14 days, followed by a 7-day washout period. Paclitaxel was given intravenously on days 1 and 8 at 80 mg/m2 for 1 h, followed by a 1-week washout period. This 3-week cycle of therapy was repeated as long as possible (at least eight cycles) until the progression of the tumor and drug-related adverse effects were no longer observed. From May 2003 to December 2005, 26 patients were enrolled in the study. The overall response rate was 53.8% (95% confidence interval, 33.4-73.4%). The clinical benefit rate, including long-term no change, was 65.4% (95% confidence interval, 44.3-82.8%). Time to progression and survival time were 297 and 1182 days, respectively, for the 26 enrolled patients. No severe toxicities were observed. Grade 3/4 leucopenia in three patients, neutropenia in five patients, increased serum creatinine in three patients, hypercalemia in one patient, hypocalcemia in one patient, nausea/vomiting in two patients, and diarrhea in one patient. The good response rate and long time to progression and overall survival time of this doxifluridine combined with weekly paclitaxel therapy indicate its potential as a first-line or second-line treatment for advanced or recurrent breast cancer patients.

膵癌, 慢性膵炎, 急性膵炎の超音波像の同じ所見における出現率を比較検討した. 対象は膵癌15症例, 慢性膵炎14症例, 急性膵炎9症例である. 膵癌に高頻度に現れる所見は辺縁の不整, 腫瘤部の低エコー, 総胆管拡張, 限局性腫大, 腫瘤部エコースポットの不均一性, 肝管, 膵管の拡張であった. 出現頻度は少ないが, 他の膵疾患にない膵周囲血管, リンパ節の異常, 膵後方エコーの減弱も重要な所見と考える. 慢性膵炎に高頻度に現れる所見はspotty echo (不均一な点状, 斑状エコーの増強), 辺縁の不整, 低エコーであり, 出現頻度は少ないが膵の萎縮, 膵石エコーも重要な所見と考える. 軽症例においては必ずしも種々の異常所見を呈さないことがわかった. 急性膵炎に高頻度に現れる所見は, びまん性腫大, 低エコー, エコースポットの不均一性であった.